Sidley Represents Gilead in US$3 Billion Senior Unsecured Notes Offering

Sidley represented Gilead Sciences, Inc. (Nasdaq: GILD) in connection with its underwritten, registered public offering of US$3 billion aggregate principal amount of US$500 million of 4.250% senior notes maturing in 2028, US$1 billion of 4.400% senior notes maturing in 2029, US$1 billion of 4.600% senior notes maturing in 2031, and US$500 million of 4.900% senior notes maturing in 2034.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades. The company intends to use the net proceeds from this offering for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions, or other business opportunities.

The Sidley team was led by Rob Ryan and Kayla West (Capital Markets), and included Chloé Marks, David Hoff, and Samayra Siddiqui (Capital Markets); Robert Kreitman and Morgan Ross (Tax); Meena Datta, Mark Langdon, and Meghan Weinberg (Healthcare); Torry Cope, Kevin A. Sforza, and paralegal Liisi V. Fletcher (Food, Drug and Medical Device); and Carla G. Teodoro (Investment Funds).